You are here

Our science / Clinical Trials / Find a Trial / NCT03643211

Xeljanz Special Investigation for Long-term Use in UC Patients

Back to Search Print Save as PDF Bookmark Trial

NCT03643211

Last updated on September 7, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Local Country Office
Tokyo, , Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ulcerative Colitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with ulcerative colitis treated with XELJANZ

- Patients naive to XELJANZ in the treatment of ulcerative colitis

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- None

NCT03643211
Pfizer
Recruiting
Xeljanz Special Investigation for Long-term Use in UC Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT04090411
All Genders
Ulcerative Colitis
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
NCT04071405
All Genders
18+
Years
Seoul,
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
NCT02925338
All Genders
6+
Years
Multiple Sites
Ulcerative Colitis
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
NCT03269695
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now